Ocugen, Inc. (OCGN): Nasdaq/NYSE listing notice — Ocugen receives 180-day extension from Nasdaq to April 29, 2024 to regain $1 bid price compliance

Ocugen, Inc.

Nasdaq granted Ocugen an additional 180-day extension until April 29, 2024 to meet minimum $1.00 bid price requirement.
Company initially received bid price deficiency notice on May 1, 2023; first compliance period ended Oct 30, 2023.
Stock has been below $1.00 for over 30 consecutive business days; no assurance of regaining compliance.
Ocugen intends to monitor closing bid price and consider options to regain compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Ocugen, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

October 31, 2023, the Company received notice from Nasdaq stating that, although we had not regained compliance with the minimum bid price requirement, Nasdaq determined that we are eligible for an additional 180-day period, or until April 29, 2024, to regain compliance with the minimum bid price requirement. The Company intends to monitor closely the closing bid price of its common stock and to consider plans for regaining compliance with Rule 5550(a)(2). While the Company plans to review all available options, there can be no assurance that it will be able to regain compliance with the appli

View on SEC.gov

Browse all listing & compliance notices →

Ocugen, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-036087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.